Similarly, Bcl-2 overexpression has been associated with acquired resistance of pancreatic carcinoma [32] corresponding to our data which show upregulation X-IAP and to a somehow weaker extent of Bcl-2 in response to DEX. This evidence concerns the gene BCL2 and exocrine pancreatic carcinoma.